Our Bureau

New Delhi, Aug. 4

Ranbaxy Laboratories Ltd announced on Friday that it has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture and market Risperidone oral solution (1 mg/mL).

Risperdal (risperidone) is indicated for the treatment of schizophrenia.

The total annual market sales for risperidone oral solution were at $66 million. "We are pleased to receive this tentative approval for Risperidone oral solution.

This product represents a future opportunity for Ranbaxy and will be launched following final approval from the USFDA," Mr Jim Meehan, Vice-President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc, said.

Ranbaxy Pharmaceuticals Inc is a wholly owned subsidiary of Ranbaxy Laboratories Ltd. It is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

(This article was published in the Business Line print edition dated August 5, 2006)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.